Libtayo is approved for adjuvant treatment in high-risk CSCC patients post-surgery and radiation, showing significant disease-free survival benefits in the C-POST trial. The C-POST trial excluded ...
Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback